Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Kritika Sarmah

Earnings Preview: What To Expect From Moderna’s Report

Valued at a market cap of $23.7 billion, Moderna, Inc. (MRNA) is a biotechnology company focused on developing messenger RNA (mRNA)-based medicines and vaccines. Headquartered in Cambridge, Massachusetts, Moderna aims to use mRNA technology to instruct the body's cells to produce proteins that can prevent or treat diseases.

The biotech titan is expected to announce its fiscal Q2 earnings for 2026 before the market opens on Friday, Jul. 31. Ahead of this event, analysts expect this biotechnology company to report a loss of $1.97 per share, an improvement of 7.5% from a loss of $2.13 per share in the year-ago quarter. The company has topped Wall Street’s bottom-line estimates in each of the last four quarters.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.